>>> US Research Calls I

Research Calls I
  • Upgrades:
    • Asana (ASAN) upgraded to Neutral from Underweight at Piper Sandler; tgt lowered to $16
    • Bilibili (BILI) upgraded to Buy from Neutral at UBS; tgt raised to $18
    • Century Communities (CCS) upgraded to Neutral from Underperform at Wedbush; tgt $82
    • Fifth Third (FITB) upgraded to Outperform from Peer Perform at Wolfe Research; tgt $43
    • Hancock Whitney (HWC) upgraded to Outperform from Mkt Perform at Keefe Bruyette; tgt $55
    • Heartland Financial (HTLF) upgraded to Outperform from Mkt Perform at Keefe Bruyette; tgt $54
    • Hormel Foods (HRL) upgraded to Neutral from Underweight at JP Morgan; tgt raised to $29
    • Independent Bank Group (IBTX) upgraded to Overweight from Underweight at Piper Sandler; tgt raised to $58
    • NetApp (NTAP) upgraded to Neutral from Underweight at JP Morgan; tgt raised to $125
    • Seacoast Banking (SBCF) upgraded to Outperform from Mkt Perform at Keefe Bruyette; tgt $27
    • UMB Financial Corporation (UMBF) upgraded to Outperform from Mkt Perform at Keefe Bruyette; tgt $98
    • Wynn Resorts (WYNN) upgraded to Buy from Neutral at Seaport Research Partners; tgt $116
  • Downgrades:
    • Cactus (WHD) downgraded to Accumulate from Buy at Johnson Rice
    • ConnectOne Bancorp (CNOB) downgraded to Mkt Perform from Outperform at Keefe Bruyette
    • OceanFirst Finl (OCFC) downgraded to Mkt Perform from Outperform at Keefe Bruyette; tgt $18
    • Valley National (VLY) downgraded to Mkt Perform from Outperform at Keefe Bruyette; tgt $8
  • Others:
    • Abacus Life (ABL) initiated with a Buy at B. Riley Securities; tgt $16
    • AC Immune (ACIU) initiated with a Buy at BTIG Research; tgt $8
    • Agree Realty (ADC) initiated with a Neutral at UBS; tgt $60
    • Allogene (ALLO) initiated with an Overweight at Piper Sandler; tgt $11
    • Apellis Pharmaceuticals (APLS) initiated with a Neutral at Piper Sandler; tgt $46
    • Arcellx (ACLX) initiated with an Overweight at Piper Sandler; tgt $70
    • Ascendis Pharma (ASND) initiated with a Buy at Stifel; tgt $200
    • Beazer Homes (BZH) initiated with an Outperform at Oppenheimer; tgt $37
    • BHP Group (BHP) resumed with a Buy at Citigroup
    • Birkenstock Holding Plc (BIRK) initiated with a Buy at William O'Neil
    • Elevation Oncology (ELEV) initiated with an Overweight at Piper Sandler; tgt $10
    • Essential Properties Realty Trust (EPRT) initiated with a Buy at UBS; tgt $30
    • Federal Signal (FSS) initiated with an Outperform at William Blair
    • Immunome (IMNM) initiated with an Overweight at Piper Sandler; tgt $27
    • Landsea Homes (LSEA) initiated with an Outperform at Oppenheimer; tgt $14
    • Lemaitre Vascular (LMAT) resumed with a Buy at ROTH MKM; tgt $100
    • Lionsgate Studios (LION) initiated with a Buy at Citigroup; tgt $14
    • New Gold (NGD) resumed with an Outperform at BMO Capital Markets
    • NNN REIT (NNN) initiated with a Neutral at UBS; tgt $41
    • Ocular Therapeutix (OCUL) resumed with an Overweight at Piper Sandler; tgt $15
    • PayPal (PYPL) initiated with a Buy at New Street; tgt $80
    • Quad/Graphics (QUAD) initiated with a Buy at Rosenblatt; tgt $7.50
    • Regulus Therapeutics (RGLS) initiated with a Buy at JonesTrading
    • Rubrik (RBRK) initiated with an Overweight at Cantor Fitzgerald; tgt $50
    • Sarepta Therapeutics (SRPT) initiated with an Overweight at Piper Sandler; tgt $157
    • Solid Biosciences (SLDB) resumed with an Overweight at Piper Sandler; tgt $20
    • Vestis (VSTS) initiated with a Mkt Perform at William Blair
    • W.P. Carey (WPC) initiated with a Neutral at UBS; tgt $57

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • MDB -24.4%, DELL -15.5%, S -13.5%, VEEV -8.6%, JWN -6.1%, MRVL -5.7%, DOOO -3.9%, COST -0.6%
Other news:
  • GYRE -3.9% (files mixed shelf and secondary stock offering)
  • FLUT -3.1% (announces CFO transition)
  • PRLD -2.1% (files $400 mln mixed shelf)
  • CRBG -2% (AIG announces pricing of secondary offering of Corebridge Financial consisting of 30 mln shares of common stock at $29.20 per share)
  • GILD -1.8% (update on Phase 3 study)
  • RARE -1.7% (positive top-line results)
  • ADPT -1.7% (announces data supporting the clinical benefits of MRD assessment with clonoSEQ to be presented at the upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress)
  • PTON -1.4% (completes $1.35 bln refinancing)
  • LGND -1.1% (Ligand Pharma completed purchase of certain Agenus (AGEN) royalty rights)
  • SHBI -0.8% (files $175 mln mixed shelf)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • GPS +23.9%, AMBA +20%, ZS +15.5%, ASAN +12.3%, GCO +9%, ESTC +7.9%, ULTA +7.7%, PD +6.9% (also authorized $100 mln for repurchases), COO +3.3%, IBTA +2.1%, PHR +2%, NTAP +1.6%
Other news:
  • QSI +12.2% (CEO to serve as independent Chairman)
  • VFC +5.4% (appoints new President of Vans)
  • LRMR +4.1% (FDA selected to participated in START program)
  • MLAB +3.2% (delayed earnings release - working to finalize our year end audit which is focused on finalizing the calculations and technical accounting for previously-announced impairments of long-lived assets and goodwill related to our Clinical Genomics and Biopharmaceutical Development divisions and the purchase accounting associated with the acquisition of GKE)
  • BPMC +3.1% (announces Data Presentations at EAACI and EHA Annual Meetings Highlighting Sustained Clinical Benefits of AYVAKIT/AYVAKYT)
  • VERV +2.7% (announces leadership update)
  • JSPR +1.6% (to Present Data on Briquilimab in Mast Cell Driven Diseases at the EAACI Congress 2024)
  • NVS +1.3% (reports Phase III data confirming sustained efficacy and long-term safety of oral remibrutinib in chronic spontaneous urticaria)
  • IONS +1.2% (presents positive results from OASIS-HAE and OASISplus studies of investigational medicine donidalorsen in patients with hereditary angioedema)

WSJ : Bill Ackman Eyes IPO of Pershing Square

Bill Ackman Eyes IPO of Pershing Square
Rare hedge-fund firm listing aims to capitalize on investor’s record and newfound celebrity

Bill Ackman is planning to take his investment firm public as soon as next year, the boldest move yet by the hedge-fund manager to capitalize on his social-media fame.

As a precursor to a public listing, Ackman is selling a stake in the firm, Pershing Square, to investors in a funding round expected to value the firm at about $10.5 billion, people familiar with the matter said. That deal is expected to close in the coming days.

Pershing Square managed about $16.3 billion in net assets as of the end of April; other asset managers with valuations in the same ballpark manage several times that.

Pershing Square has been telling investors its valuation is warranted because it plans to bring in billions more in sticky assets. Today it primarily holds a concentrated portfolio of stocks of large companies it believes are undervalued, including Chipotle Mexican Grill CMG 1.07%increase; green up pointing triangle and Universal Music Group.

Such a listing, should one happen, would be an anomaly in the world of hedge funds. After a burst of debuts just before the 2008-09 financial crisis, public markets soured on hedge-fund firms. The management and performance fees that make up hedge funds’ revenues can be unpredictable, assets can shrink if investors yank their money out, and returns can be volatile.

The market hasn’t been welcoming to new issues in general the past few years, though a string of successful initial public offerings this year suggest it could be turning a corner. Ackman isn’t planning to take his firm public until late 2025 or early in 2026, some of the people said.

Pershing Square has been refashioning itself into an asset manager with durable capital and less noise. Nearly all of its capital is now tied up in a closed-end fund, Pershing Square Holdings, whose shares trade on European stock exchanges. It has backed off of the bruising proxy battles and activist short selling that once defined the firm.

An IPO would punctuate a frenetic period for Ackman, a prominent investor who supercharged his profile with social crusades on X, formerly known as Twitter. His causes included campaigning to oust university presidents he saw as being too accommodative of antisemitism on campus.

Pershing Square received regulatory approval last year for a new type of investment vehicle that would buy a stake in a private company and take it public. Earlier this year, Ackman’s firm filed a prospectus for a new closed-end fund aimed at individual investors in the U.S. called Pershing Square USA.

His “brand-name profile and broad retail following, along with a substantial media following, will drive substantial investor interest,” the prospectus said. One of the people familiar with the matter said Ackman plans to write about new investments on X once the retail fund gets approved. (He is currently barred from marketing his Europe-listed fund to U.S. investors.)

About half of the roughly $1 billion Pershing Square raised in the pre-IPO round will be invested into Pershing Square U.S.A. upon its launch, which could happen as soon as July. The rest will anchor investments in funds Ackman plans to launch later on.

Pershing Square has told potential investors to compare it to asset managers like Brookfield Asset Management and Blue Owl Capital rather than hedge funds. Brookfield’s market value is about $15 billion; it has more than $925 billion in assets under management. Blue Owl’s market value is about $28 billion and it manages more than $174 billion.

The firm justified its rich valuation to investors by explaining that it expects to manage considerably more money, and eventually earn more in fees, after Pershing Square U.S.A. and other funds launch, people familiar with the matter said.

One potential hurdle in winning assets: the replicability of Pershing Square’s portfolio, which had 10 disclosed positions as of April.

Investors who tried to go that route previously missed out on gains as the firm built positions, a person familiar with the matter said. They also missed out on complex hedging strategies that don’t need to be disclosed.

Ackman is Pershing Square’s largest shareholder and stands to increase his net worth, estimated at $4.3 billion by Forbes, with a successful IPO of his management company. The move could also help retain talent and aid in succession planning, the people familiar with the matter said.

Ackman started Pershing Square in 2004 as an activist hedge-fund firm. It scored high-profile wins on Wendy’s and mall developer General Growth Properties.

He suffered a losing streak between 2015 and 2017 when big bets on drugmaker Valeant Pharmaceuticals and against supplement-maker Herbalife backfired. Since then, Pershing Square has been riding high. The firm made more than $5 billion in gains on hedging trades tied to the Covid-19 pandemic.

The European fund’s five-year average annualized return as of the end of 2023 was 31.2%, about double that of the comparable return of the S&P 500, including dividends. It gained 5.4% this year through April, after fees.

>>> Soho House & Co issued the following statement (5.33)

Soho House & Co issued the following statement (5.33)
  • As previously announced, the Board of Directors of the Company established an independent Special Committee of the Board in the fall of 2023 to evaluate certain strategic transactions, which included potentially becoming a private company. This was instigated because the Company received interest from a party that conditioned a proposal on certain Class B holders rolling over their equity interests in the Company as part of a transaction.
  • The offer received from the party was at a value that reflected a substantial premium over the current trading price. After thorough review by the Special Committee and its independent advisors, the Special Committee concluded that the offer did not adequately reflect the value of the Company and was not in the best interests of its public stockholders. Consequently the Special Committee has requested that the Board dissolve the Special Committee, which it has done. The Board has the ability to establish such a committee in the future.

>>> US Early premarket gappers

Early premarket gappers
  • Gapping up:
    • GPS +23.1%, AMBA +17.8%, ZS +17.1%, ASAN +13.2%, PD +10.9%, ESTC +8.4%, ULTA +7%, HTZ +6.9%, VFC +6.7%, LRMR +4.1%, COO +3.3%, MLAB +3.2%, BPMC +3.1%, AGEN +3.1%, PHR +2%, JSPR +1.6%, NTAP +1.3%, RARE +0.9%
  • Gapping down:
    • MDB -25%, DELL -15.3%, S -14%, VEEV -7.8%, JWN -7.4%, DOOO -6.6%, MRVL -5%, GYRE -3.9%, PRLD -2.1%, PTON -2%, GILD -1.7%, CRBG -1.5%, COST -1.5%, LGND -1.1%, SHBI -0.8%, REGN -0.8%

>>> Europe : Brokers Upgrades & Downgrades - 31st of May 2024 V3(++)

>>> Up
* Alior Raised to Neutral at JPMorgan; PT 96 zloty
* Ambarella PT Raised to $67 from $57 at Morgan Stanley (+)
* Azelis Raised to Neutral at UBS; PT 20 euros (++)
* Cellnex Raised to Buy at Deutsche Bank (+)
* Centrica Raised to Outperform at RBC; PT 170 pence
* Costco PT Raised to $855 from $780 at Morgan Stanley (+)
* Foot Locker PT Raised to $24 from $20 at Morgan Stanley (+)
* Gap PT Raised to $27 from $20 at Morgan Stanley (+)
* Gap PT Raised to $23 from $18 at BMO (++)
* Great Portland Raised to Buy at Shore Capital (++)
* PKO Bank Polski Raised to Overweight at JPMorgan; PT 84.50 zloty
* Quilter Raised to Neutral at Citi; PT 113 pence

>>> Down
* Alphawave IP Cut to Hold at Jefferies; PT 155 pence
* Assura Cut to Hold at Shore Capital (++)
* Avance Gas Cut to Hold at ABG; PT 174 kroner (++)
* BW LPG Cut to Hold at ABG; PT 226 kroner (+)
* Calliditas Therapeutics ADRs Cut to Neutral at Citi; PT $39
* Capgemini Cut to Neutral at JPMorgan; PT 210 euros
* Capgemini Cut to Hold at Jefferies; PT 195 euros
* CT Private Equity Trust Cut to Hold at Stifel (++)
* Fluidra Cut to Hold at Bestinver; PT 24.25 euros
* Guess PT Cut to $25 from $29 at Jefferies (++)
* MTG Cut to Hold at ABG; PT 102 kronor
* Neoen Cut to Hold at Stifel; PT 39.85 euros

>>> Initiation
* BHP Resumed Buy at Citi; PT 2,600 pence
* Birkenstock Rated New Buy at William O'Neil (++)
* Feintool Rated New Outperform at Oddo BHF; PT 27 Swiss francs
* RedFish LongTerm Capital Rated New Buy at Alantra Equities
* Spinnova Rated New Accumulate at Inderes; PT 2 euros (++)

>>> Call
* Capgemini Slides as JPMorgan, Jefferies Cut on Weak IT Demand (++)
* Centrica Gains after RBC Upgrade on Strong Balance Sheet (++)

>>> Europe : Brokers Upgrades & Downgrades - 31st of May 2024 V2(+)

>>> Up
* Alior Raised to Neutral at JPMorgan; PT 96 zloty
* Ambarella PT Raised to $67 from $57 at Morgan Stanley (+)
* Cellnex Raised to Buy at Deutsche Bank (+)
* Centrica Raised to Outperform at RBC; PT 170 pence
* Costco PT Raised to $855 from $780 at Morgan Stanley (+)
* Foot Locker PT Raised to $24 from $20 at Morgan Stanley (+)
* Gap PT Raised to $27 from $20 at Morgan Stanley (+)
* PKO Bank Polski Raised to Overweight at JPMorgan; PT 84.50 zloty
* Quilter Raised to Neutral at Citi; PT 113 pence

>>> Down
* Alphawave IP Cut to Hold at Jefferies; PT 155 pence
* BW LPG Cut to Hold at ABG; PT 226 kroner (+)
* Calliditas Therapeutics ADRs Cut to Neutral at Citi; PT $39
* Capgemini Cut to Neutral at JPMorgan; PT 210 euros
* Capgemini Cut to Hold at Jefferies; PT 195 euros
* Fluidra Cut to Hold at Bestinver; PT 24.25 euros
* MTG Cut to Hold at ABG; PT 102 kronor
* Neoen Cut to Hold at Stifel; PT 39.85 euros

>>> Initiation
* BHP Resumed Buy at Citi; PT 2,600 pence
* Feintool Rated New Outperform at Oddo BHF; PT 27 Swiss francs
* RedFish LongTerm Capital Rated New Buy at Alantra Equities

>>> Call